Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. (Q50882866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Xavier Pivot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

M C Etienne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M Lavit

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

A Pujol

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P Canal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Milano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

92-97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Influence of sex and age on fluorouracil clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Hepatic drug metabolism and aging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900345-6

7 January 2021

10.1016/S0959-8049(97)00345-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9624244%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference